GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Seeking Alpha's Quant system consistently outperforms the S&P 500 ( SP500 ), driven by powerful computer processing and SA's ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling ... 2025 Chinese tech company Alibaba on Wednesday released a new version of its Qwen ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly and Company (LLY) is a global leader in healthcare ... medicines to address some of the world's most pressing medical needs. With a market cap of $759.4 billion, Eli Lilly operates ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... ll have a lot of winners with these drug and medical device plays.” For this article, we compiled a list ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...